• Overview
  • Eligibility
  • More info
  • Locations

A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD (NCT03024346)

Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance With Moderate to Severe COPD.
  • Drug: GFF MDI (PT003) 14.4/9.6μg
    Glycopyrronium and Formoterol Fumarate
    • GFF
  • Drug: Placebo MDI
    Glycopyrronium and Formoterol Fumarate
    • GFF
Ages eligible for Study
40 Years to 80 Years
Genders eligible for Study
All
Accepts Healthy Volunteers
No
A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.

1 locations

Belgium (1)
  • Pearl Investigator Site
    Not specified
    Antwerp, Belgium
Status:
completed
Type:
Interventional
Phase:
Start:
31 December, 2015
Updated:
12 February, 2017
Participants:
20
A girl giving information about available additional trials.

FindMeCure helps you find, understand and join clinical trials from all over the world.

There are more clinical trials for your condition!